Mammalian Cell Fermentation Technology Market - By Type (Chinese Hamster Ovary (CHO), Human Embryonic Kidney (HEK)), Application (Monoclonal Antibodies, Recombinant Proteins), End-use (Biopharmaceutical Companies, CMOs & CDMOs) & Forecast, 2023-2032

Mammalian Cell Fermentation Technology Market Size

Mammalian Cell Fermentation Technology Market size was valued at USD 38 billion in 2022 and is expected to reach USD 80.5 billion by 2032, registering a CAGR of 8.4% between 2023 - 2032. High market growth can be attributed to the escalating demand for biologics, such as monoclonal antibodies, vaccines, and therapeutic proteins, that has stimulated the adoption of mammalian cell fermentation technology to efficiently produce these complex molecules.
 

Also, the growing emphasis on precision medicine has led to a surge in the development of cell-based therapies and personalized biologics, further propelling the utilization of these technology to ensure reliable and consistent production of tailored medical treatments. Furthermore, ongoing research and development efforts to optimize bioprocessing methods, coupled with the growing investments in biomanufacturing infrastructure, are further fostering the market's progress.
 

Mammalian cell fermentation technology, also known as mammalian cell culture technology, refers to the process of growing and cultivating mammalian cells in a controlled environment for various purposes, such as biopharmaceutical production, research, and the development of therapeutic proteins, vaccines, and other bioproducts. This technology involves creating a suitable environment that mimics the natural conditions required for mammalian cells to grow and reproduce.
 

COVID-19 Impact

The COVID-19 pandemic had a positive impact on the mammalian cell fermentation technology market. As the world raced to develop vaccines and therapeutic solutions, the demand for biopharmaceutical products escalated. This surge in demand, coupled with the urgency to streamline production processes, prompted significant advancements in mammalian cell fermentation technology. The urgent need for vaccines, diagnostics, and therapies also accelerated the demand for mammalian cell-based biomanufacturing, particularly in the production of recombinant proteins and viral vectors.
 

Biopharmaceutical companies rapidly adopted innovative approaches to optimize cell culture systems, enhance fermentation yields, and improve overall efficiency. Moreover, the pandemic highlighted the crucial role of mammalian cell fermentation in drug development and production, driving increased investments, research, and collaboration, ultimately fostering a more resilient and advanced industry poised for future challenges.
 

Mammalian Cell Fermentation Technology Market Trends

The market is experiencing a robust surge, driven primarily by the increasing demand for biologics. Biologics, which encompass a wide range of therapeutic proteins, antibodies, enzymes, and vaccines derived from living cells, have revolutionized the pharmaceutical and healthcare industries. As these complex molecules offer highly targeted and effective treatments for various diseases, including cancer, autoimmune disorders, and infectious diseases, their demand continues to rise. Mammalian cell fermentation serves as a critical process for the production of these biologics, providing a platform for the cultivation and expression of genetically engineered mammalian cells that produce the desired therapeutic proteins.
 

Furthermore, the growth in demand for biologics, owing to their specificity, efficacy, and reduced side effects compared to traditional small-molecule drugs, directly translates into a heightened need for efficient and scalable mammalian cell fermentation processes, thereby driving the market trends.
 

Mammalian Cell Fermentation Technology Market Restraint

A significant restraint hindering the widespread adoption of this technology is the high cost associated with its production process. The cultivation of mammalian cells demands precise and controlled conditions, extensive quality control measures, and specialized facilities, all of which contribute to elevated operational expenses. Also, the production yields in mammalian cell fermentation can be comparatively lower than those achieved through other methods, resulting in the need for larger cultures and extended production times to meet the desired quantities. These factors collectively contribute to the elevated costs of biologic manufacturing using mammalian cell fermentation, limiting its accessibility and affordability, particularly for smaller biotech companies and healthcare systems with constrained resources, thereby hampering widespread adoption of these technology.
 

Mammalian Cell Fermentation Technology Market Analysis

By type, the mammalian cell fermentation technology market is segmented into Chinese hamster ovary (CHO) cell fermentation, human embryonic kidney (HEK) cell fermentation, baby hamster kidney (BHK) cell fermentation, murine myeloma cell fermentation, and other types. The Chinese hamster Ovary (CHO) cell fermentation segment held largest market share of 65.2% in 2022. CHO cells have garnered immense attention due to their capacity to efficiently produce complex therapeutic proteins. The surge in demand can be attributed to several factors, including advancements in genetic engineering techniques for enhancing cell line development, optimization of culture media and conditions, and a robust regulatory environment. The versatility of CHO cells in producing monoclonal antibodies, vaccines, and other biologics has positioned them as the preferred choice for many pharmaceutical and biotechnology companies, thereby aiding in high segment growth.
 

By application, the mammalian cell fermentation technology market is segmented into monoclonal antibodies, recombinant proteins, vaccines, hormones, enzymes, and other applications. The monoclonal antibodies segment held highest business share of 41.9% in 2022. High adoption can be attributed to the pivotal role that antibodies play in therapeutic and diagnostic applications, leading to increased demand for efficient production methods. Also, segment's rapid growth is fuelled by advancements in bioprocessing techniques, cell line development, and bioreactor technologies, resulting in enhanced yields, improved product quality, and streamlined production processes. Moreover, the rising prevalence of chronic diseases and the need for precise targeted therapies have further amplified the demand for mammalian antibodies.
 

Based on end-use, the mammalian cell fermentation technology market is segmented into CMOs & CDMOs, biopharmaceutical companies, and academic & research institutes. The CMOs & CDMOs segment dominated the market in 2022 with a revenue of USD 19.8 billion. High demand for CMOs & CDMOs can be attributed to advanced manufacturing capabilities that CMOs and CDMOs specialize in. These organizations offer a streamlined and cost-effective approach for companies aiming to outsource their production processes, enabling them to focus on research and development.
 

Moreover, regulatory requirements and quality standards have become more stringent, making it vital for pharmaceutical companies to collaborate with established CMOs and CDMOs that possess the expertise to meet these standards. Further, as the biopharmaceutical sector continues to expand, the CMOs and CDMOs specializing in mammalian cell fermentation are poised to play a pivotal role in shaping the industry's landscape, driving innovation, and ensuring the efficient delivery of cutting-edge therapies to patients across the globe.
 

North America dominated the mammalian cell fermentation technology market in 2022, with a revenue of USD 18.2 billion and is anticipated to grow at a CAGR of 7.9% between 2023 – 2032. This growth can be attributed to the thriving biopharmaceutical industry in the region. The region's focus on innovation, coupled with a strong foundation in scientific expertise and infrastructure, has propelled it to the forefront of market growth. Moreover, favorable regulatory frameworks, increased investment in biotechnology R&D, growing demand for biologics and personalized medicine have further propelled the North American market expansion.
 

Mammalian Cell Fermentation Technology Market Share

Major market players operating in the mammalian cell fermentation technology market include

• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Danaher
• Lonza
• F. Hoffmann-La Roche Ltd
• Sartorius AG
• AstraZeneca
• Bristol-Myers Squibb
• Amgen
• Gilead Sciences
• Moderna, Inc.
• Regeneron Pharmaceuticals

These industry players majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
 

Mammalian Cell Fermentation Technology Industry News:

• In July 2023, Lonza launched the TheraPRO CHO media system, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines. This helped the company expand its product offerings.
   
• In October 2018, Thermo Fisher Scientific Inc. acquired the advanced bioprocessing business from BD (Becton, Dickinson and Company). BD Advanced Bioprocessing includes cell culture media, supplements, and feeds designed to work in a variety of biopharmaceutical applications—including the production of vaccines, monoclonal antibodies, and biosimilars. This strategy helped the company to strengthen its mammalian cell fermentation portfolio.
   

The mammalian cell fermentation technology market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By Type

• Chinese Hamster Ovary (CHO) cell fermentation
• Human Embryonic Kidney (HEK) cell fermentation
• Baby Hamster Kidney (BHK) cell fermentation
• Murine myeloma cell fermentation
• Other types

By Application

• Monoclonal antibodies
• Recombinant proteins
• Vaccines
• Hormones
• Enzymes
• Other applications

By End-use

• Biopharmaceutical companies
• CMOs & CDMOs
• Academic & research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA